Advanced Allergy Services LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$32,902	1
2023	Research	$53,556	6
2022	Research	$140,263	16
2021	Research	$288,391	16
2020	Research	$129,941	6
2019	Research	$386,430	11

Breakdown

Who paid Research payments · program years 2019–2024

Regeneron Pharmaceuticals, Inc. $591,535 21 payments
Merck Sharp & Dohme Corporation $196,738 5 payments
Shire North American Group Inc $119,069 4 payments
Pharming Healthcare, Inc. $112,874 3 payments
Takeda Pharmaceuticals U.S.A., Inc. $11,267 23 payments

Studies the money was for Research payments · program years 2019–2024

Utility of functionally relevant signature genes in assessing clinical outcomes of dupilumab treatment in adult onset atopic dermatitis/Advanced Allergy Services $558,633 20 payments
Investigation of Pathomechanisms Of Chronic Cough Using In Vitro Approaches $126,750 2 payments
Discovering Potential Peripheral Blood Biomarkers for Diagnosis and Management of Hereditary Angioedema Attacks $119,069 4 payments
Treatment of Hereditary Angioedema Prodrome With Recombinant Human C1-Esterase Inhibitor Ruconest $112,874 3 payments
Investigation of Epidemiologic Characteristics And Economic Burden Of Chronic Cough Using A Large Electronic Medical Record Longitudinal Database $35,000 2 payments
Investigation of Epidemiology Of Chronic Cough Using An Electronic Questionnaire Survey using REDCap $34,988 1 payment
Utility of Functionally Relevant Signature Genes in Assessing Clinical Outcomes of Dupilumab Treatment in Adult Onset Atopic Dermatitis $32,902 1 payment
An Observational, Non-Interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (Empower Study) $6,301 20 payments
An Observational, Non-Interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (Empower Study) $4,966 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.